Dr. Franco received his doctorate in Chemical Science from the Universidad Complutense (Madrid) in 1971. He has been member of the Royal Academy of Exact, Physical, and Natural Sciences since 2002 and of the Valencian Autonomous Community’s Royal Academy of Medicine and Science (Reial Acadèmia de Medicina i Ciències de la Comunitat Valenciana) since 2010. He is now an Emeritus Senior Professor of Biochemistry and Molecular Biology at the University of Valencia, and previously served as an assistant professor (1973-1975) and associate professor (1975-1981) in Biochemistry at the Universidad Complutense.
He was Vice-dean of the Faculty of Biochemistry and Director of the Biochemistry and Molecular Biology Department at the University of Valencia, Director of the Chemistry Institute at the Valencian Institution of Studies and Research (IVEI; Institución Valenciana de Estudios e Investigación), and was appointed the university advisor by the Senate.
He specialized in the study of chromatin because of his postdoctoral stay at the Chester-Beatty Research Institute in the Royal Cancer Hospital (London). He still works in this line of investigation, and now takes a particular interest in the role of epigenetic modifications in colorectal cancer. Since 1979 he has been the Principal Investigator of several competitive research projects on epigenetics and chromatin. He has also been the Principal Investigator on two company contracts and has supervised 20 doctoral theses.
Apart from 2 books, 3 monographs, and 12 revisions, he has published more than a hundred research articles in international journals. He is also the author of numerous articles and publications about Bioethics.
He has helped to organize several conferences and national and international scientific meetings and has been invited to present numerous papers at international conferences. He has also given several university lectures at Spanish and foreign research centers.
He is member of several Scientific Societies and he regularly participates in evaluating research projects for several national and international agencies and manuscripts for many international journals.
Bioinformatic analysis of work on the antitumor effect of Gas1 transfection, in collaboration with the INCLIVA Bioinformatics service.
• This group has obtained and characterized anti-Ac-hnRNP-L antibodies which will serve as a tool in subsequent experiments.
• Similarly, they have obtained HAE6 Cell (KRAS gene KO/mutant) and HAF1 (wt/KO) clones which are stably transformed with the hnRNP-L and Set2 genes; work has already started to study the differential interactome of these proteins.
• Immunoprecipitation experiments suggest that the p300 enzyme participates in the hyperacetylation of hnRNP-L in KRAS mutants. Experiments to silence this enzyme with siRNAs have also started.